Jupiter Neurosciences announced a strategic initiative to support individuals on GLP-1–based weight loss therapies by expanding its Nugevia™ consumer longevity line. The company highlighted that rapid weight loss via GLP-1 receptor agonists can stress mitochondrial energy production, lean tissue preservation and neuro-gut inflammatory balance. To address these concerns, Jupiter plans to commercialize two formulations—Nugevia™ MND and Nugevia™ PWR—leveraging its JOTROL™ resveratrol platform, which has demonstrated a threefold increase in bioavailability in preclinical studies. Jupiter cites a 4,600% surge in online searches for “Ozempic face” and a report in the Aesthetic Surgery Journal indicating patients with significant weight loss may appear up to five years older, positioning Nugevia as a science-driven supplement to mitigate those effects.

Genentech reported positive topline data from CT388-103, a Phase II trial of CT-388, its investigational dual GLP-1/GIP receptor agonist. In 469 participants with obesity or overweight and at least one comorbidity, once-weekly injections titrated to 24 mg achieved a placebo-adjusted mean weight loss of 22.5% at 48 weeks (efficacy estimand) and 18.3% (p < 0.001) under treatment-regimen analysis. At the highest dose, 95.7% of subjects lost ≥5% of body weight, 87.0% ≥10%, 47.8% ≥20% and 26.1% ≥30%. Among 73% of pre-diabetic participants treated with 24 mg CT-388, normal blood glucose levels were restored by week 48 versus 7.5% in placebo. Adverse events were predominantly mild-to-moderate gastrointestinal effects, with discontinuation rates of 5.9% for CT-388 and 1.3% for placebo. Genentech plans to advance CT-388 into two Phase III obesity trials this quarter.